Startup profile for Kalepa: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Kalepa funding, valuation and investors

AI underwriting workbench for property-and-casualty insurers and managing general agents, connecting submission intake, risk evaluation, pricing and policy binding.

Verified company research · funding, investors and latest developments

Keep track of Kalepa

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series B

$75M · November 5, 2026

Latest known valuation

$470M (basis not specified)

Series B · November 5, 2026

Total disclosed equity funding

$89M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series b · New York, NY, USA

Investors in latest funding

Lead: Updata Partners (Fund VIII)

Other: IA Ventures , Inspired Capital

Sources: latest funding · kalepa.com Last verified: 2026-11-07T00:00:00.000Z

Overview

Kalepa, founded in 2018 by Paul Monasterio and Daniel Hillman, helps commercial property-and-casualty carriers and MGAs automate submission ingestion, clearance, appetite-based triage, risk analysis, rating and quote/bind workflows.

The company reports $75M Series B funding in November 2026 led by Updata Partners, with participation from IA Ventures and Inspired Capital, at a $470M valuation; it reports $91M total funding, including a $14M 2021 Series A and earlier financing not separately quantified here. Customer outcome figures are selected company reports, not independently audited performance guarantees.

Why Kalepa is interesting

Announced $75M Series B on November 5, 2026, led by Updata Partners at a company-reported $470M valuation. Total disclosed capital $91M; precise pre/post-money valuation basis not specified in the release. Distinctive customer question: whether agent-supported triage actually improves loss ratios rather than just underwriting speed.

Product & use cases

Representative insurer workflow (illustrative, based on the company platform and lead investor's description): (1) brokers send ACORD applications, loss runs and supporting files; (2) Kalepa extracts data, checks submission completeness, sanctions and clearance; (3) its agent scores appetite fit, winnability and profitability against portfolio controls; (4) underwriters inspect the cited risk rationale and exceptions; (5) carrier rating tools/Excel models feed quote and bind documents, with human approval where required; (6) portfolio managers monitor book mix and modify guidelines. Kalepa connects to existing policy-administration systems. Enterprise pricing is quote-based/not publicly stated. This is not a hands-on product test.

  • Commercial-insurance carrier triage of email and document submissions, including ineligible or incomplete risks.
  • MGA underwriting workbench for loss-run review, exposure analysis and faster broker responses.
  • Portfolio risk managers steering concentration and appetite rather than evaluating isolated policies.
  • Broker intake cleanup for ACORD forms, loss runs and supplemental applications.

Key facts

  • November 5, 2026: $75M Series B led by Updata Partners; company-reported $470M valuation (pre/post-money status undisclosed); $91M cumulative funding.
  • 2021 Series A $14M led by Inspired Capital, with IA Ventures; Kalepa reports about $2M additional historical capital beyond these two named rounds (not reconstructed as a fictitious round).
  • Customers named by Kalepa include W.R. Berkley, Bowhead Specialty and AmRisc; implementation case studies are vendor-selected.
  • Kalepa claims 30–60% more premium per underwriter, 58% faster quotes and 960 basis-point combined-ratio improvement for reported users. These are selected, non-audited customer figures; 960bp means 9.6 percentage points, not 960%.

Funding history (newest first)

Series B

2026-11-05 $75M Valuation: $470M (basis not specified)

Source: Read source · kalepa.com

Series A (public reporting; manager release September 8)

2021-09-03 $14M

Source: Read source · prweb.com

Investors in our directory

Funds linked from Kalepa's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Updata Partners' November 5 thesis emphasizes end-to-end underwriting orchestration and direct integration into existing policy administration systems, rather than a standalone document-extraction tool. The claimed underwriting profitability results need customer-by-customer controls, consistent definitions and independent validation.

The differentiator is decision execution from submission to bind, not merely OCR. Buyers should demand documented accuracy, human override, referral controls, integration effort, policy data rights, underwriting cycle-time methodology and evidence that risk selection improves on comparable books; dollar costs and customer-wide success rates are undisclosed.

  • Guidewire incumbent

    Core insurer policy/billing/claims platform; may remain system of record when Kalepa is decision workbench.

  • Duck Creek Technologies incumbent

    Core insurance administration and policy platform; integration rather than exact substitute.

  • Sixfold direct

    AI underwriting submission and risk assessment; compare auditability and carrier workflows.

  • Federato direct

    Underwriting and portfolio steering; compare appetite controls and deployment.

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Kalepa

Practical answers founders, operators, and investors typically search for.

$75 million in a Series B led by Updata Partners, announced November 5, 2026; the company also reported a $470 million valuation without specifying whether it was pre- or post-money.
No. $91M is Kalepa's reported cumulative funding. The new round was $75M, and a disclosed 2021 Series A was $14M; the residual financing is not separately identified here.
No. They are vendor-reported results of selected insurance customers; independent controls, cohort composition and generalizability are not disclosed.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.